Compare Stocks

→ The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GANX Gain Therapeutics	$3.18 +1.0%	$4.13	$2.00 ▼ $6.19	$51.58M	0.43	156,778 shs	71,353 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GANX Gain Therapeutics	-0.94%	-6.25%	-25.88%	-5.41%	-36.62%

3 Sub-$10 Stocks to Buy for 2024 (Ad)

Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.

Get your FREE look at these THREE companies right here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GANX Gain Therapeutics	3.3122 of 5 stars	3.5	5.0	0.0	0.0	3.0	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GANX Gain Therapeutics	3.00	Buy	$8.33	162.05% Upside

Current Analyst Ratings

Latest FARN, GANX, REDX, SCLP, and TILS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/1/2024	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
3/27/2024	GANX Gain Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GANX Gain Therapeutics	$50K	1,031.59	N/A	N/A	$0.97 per share	3.28

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GANX Gain Therapeutics	-$22.27M	-$1.71	N/A	N/A	N/A	N/A	-193.03%	-123.21%	5/10/2024 (Estimated)

Latest FARN, GANX, REDX, SCLP, and TILS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/26/2024	Q4 2023	GANX Gain Therapeutics	-$0.32	-$0.29	+$0.03	-$0.29	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GANX Gain Therapeutics	0.04	3.59	3.59

Ownership

Institutional Ownership

Company	Institutional Ownership
GANX Gain Therapeutics	11.97%

Insider Ownership

Company	Insider Ownership
GANX Gain Therapeutics	11.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
GANX Gain Therapeutics	28	16.22 million	14.44 million	Optionable

FARN, GANX, REDX, SCLP, and TILS Headlines

Source	Headline
	Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher finance.yahoo.com - April 17 at 2:21 PM
	Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher zacks.com - April 17 at 10:55 AM
	Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX) zacks.com - April 10 at 10:36 AM
	Gain Therapeutics, Inc.: Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer finanznachrichten.de - April 8 at 12:50 PM
	Gain Therapeutics Appoints Gene Mack As CFO; Stock Falls markets.businessinsider.com - April 8 at 12:50 PM
	Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer globenewswire.com - April 8 at 9:25 AM
	Former Gildan CEO considered acquisition of Hanesbrands - Bloomberg msn.com - April 4 at 3:14 PM
	Gain Therapeutics, Inc. (NASDAQ:GANX) Director Buys $115,800.00 in Stock insidertrades.com - April 2 at 4:26 AM
	Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX) finance.yahoo.com - April 1 at 10:06 PM
	Buy Rating Affirmed for Gain Therapeutics on Promising Parkinson’s Treatment and Solid Financial Outlook markets.businessinsider.com - April 1 at 5:05 PM
	Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer finance.yahoo.com - April 1 at 12:04 PM
	Gain Therapeutics (NASDAQ:GANX) Stock Rating Reaffirmed by HC Wainwright marketbeat.com - April 1 at 8:30 AM
	Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Increases By 16.4% marketbeat.com - March 31 at 10:55 PM
	Optimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson’s Drug Candidate GT-02287 markets.businessinsider.com - March 28 at 1:21 AM
	Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update finanznachrichten.de - March 27 at 5:19 AM
	Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update globenewswire.com - March 26 at 8:00 AM
	Gain Therapeutics to Present at Public Ventures Discovery Day globenewswire.com - March 15 at 2:30 PM
	EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease msn.com - March 5 at 9:15 AM
	Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease finance.yahoo.com - March 5 at 9:14 AM
	Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease finance.yahoo.com - February 27 at 7:40 PM
	Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease globenewswire.com - February 27 at 2:00 PM
	Gain Therapeutics Stock (NASDAQ:GANX), Short Interest Report benzinga.com - February 23 at 12:36 PM
	GANX Mar 2024 7.500 call finance.yahoo.com - February 17 at 10:05 AM
	Gain Therapeutics, Inc.: Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight finanznachrichten.de - February 16 at 8:51 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Gain Therapeutics

NASDAQ:GANX

Gain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial